Optimizing RAAV2 Viral Vector Yield Recovery

Digital poster promoting research on enhancing rAAV2 viral vector yield recovery in upstream lysate material, presented at Advanced Therapies 2023 by Pharmaron.

Poster Authors:

Shandel Pariag, Taelor Patterson, Kirsty McManus, Lorna Kelly

Pharmaron Gene Therapy l Estuary Commerce Park, Speke, Liverpool, L24 8RB, UK

Pharmaron’s innovative adeno-associated virus (AAV) high-throughput process platform approach provides rapid access to increased titres and higher recoveries. AAV serotypes differ in their propensity to be secreted from the host cell, often requiring a lysis step to release AAV serotypes otherwise retained within the cytoplasm.

Capabilities

Knowledge Center

Connect with a Scientific Expert

Complete the form below to access resource

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.